Lara Ewert1, Anja Fischer1, Sabine Brandt1, Florian G Scurt1, Lars Philipsen2, Andreas J Müller2, Matthias Girndt3, Ana C Zenclussen4, Jonathan A Lindquist1, Xenia Gorny1, Peter R Mertens5. 1. Clinic of Nephrology and Hypertension, Diabetes and Endocrinology, Otto-von-Guericke University Magdeburg, Germany. 2. Institute for Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, Germany. 3. Department of Internal Medicine II, Martin-Luther-University Halle-Wittenberg, Halle-Saale, Germany. 4. Experimental Obstetrics and Gynecology, Otto-von-Guericke University Magdeburg, Germany. 5. Clinic of Nephrology and Hypertension, Diabetes and Endocrinology, Otto-von-Guericke University Magdeburg, Germany. Electronic address: peter.mertens@med.ovgu.de.
Abstract
BACKGROUND AND AIMS: In dialysis patients, vascular morbidities are highly prevalent and linked to leukocyte extravasation, especially of polarized monocytes. Experimental data demonstrate that phenotypic changes in monocytes require Y-box binding protein-1 (YB-1) upregulation. METHODS: We determined YB-1 expression in circulating and vessel-invading monocytes from healthy controls and dialysis patients to correlate results with intima plaque formation and systemic inflammation. RESULTS: Compared to healthy subjects, dialysis patients have fewer classical and more intermediate and non-classical monocytes. Post-translationally modified YB-1 (lysine 301/304 acetylation) is detected at high levels in the nucleus of adherent and invading CD14+CD68+ monocytes from umbilical cord and atherosclerosis-prone vessels. The content of non-acetylated YB-1 is significantly decreased (p < 0.001), whereas acetylated YB-1 is correspondingly increased (p < 0.001) throughout all monocyte subpopulations, such that the overall content remains unchanged. CONCLUSIONS: In dialysis patients the YB-1 acetylation status is higher with prevailing diabetes and intima plaque formation. Pro-inflammatory mediators TNFα, IL-6, uPAR, CCL2, M-CSF, progranulin, ANP, and midkine, as well as anti-inflammatory IL-10 are significantly increased in dialysis patients, emphasizing a systemic inflammatory milieu. Strong positive correlations of monocytic YB-1 content are seen with ANP, IP-10, IL-6, and IL-10 serum levels. This is the first study demonstrating an association of cold shock protein YB-1 expression with inflammation in hemodialysis patients.
BACKGROUND AND AIMS: In dialysis patients, vascular morbidities are highly prevalent and linked to leukocyte extravasation, especially of polarized monocytes. Experimental data demonstrate that phenotypic changes in monocytes require Y-box binding protein-1 (YB-1) upregulation. METHODS: We determined YB-1 expression in circulating and vessel-invading monocytes from healthy controls and dialysis patients to correlate results with intima plaque formation and systemic inflammation. RESULTS: Compared to healthy subjects, dialysis patients have fewer classical and more intermediate and non-classical monocytes. Post-translationally modified YB-1 (lysine 301/304 acetylation) is detected at high levels in the nucleus of adherent and invading CD14+CD68+ monocytes from umbilical cord and atherosclerosis-prone vessels. The content of non-acetylated YB-1 is significantly decreased (p < 0.001), whereas acetylated YB-1 is correspondingly increased (p < 0.001) throughout all monocyte subpopulations, such that the overall content remains unchanged. CONCLUSIONS: In dialysis patients the YB-1 acetylation status is higher with prevailing diabetes and intima plaque formation. Pro-inflammatory mediators TNFα, IL-6, uPAR, CCL2, M-CSF, progranulin, ANP, and midkine, as well as anti-inflammatory IL-10 are significantly increased in dialysis patients, emphasizing a systemic inflammatory milieu. Strong positive correlations of monocytic YB-1 content are seen with ANP, IP-10, IL-6, and IL-10 serum levels. This is the first study demonstrating an association of cold shock protein YB-1 expression with inflammation in hemodialysis patients.
Authors: Sabine Brandt; Tobias M Ballhause; Anja Bernhardt; Annika Becker; Delia Salaru; Hien Minh Le-Deffge; Alexander Fehr; Yan Fu; Lars Philipsen; Sonja Djudjaj; Andreas J Müller; Rafael Kramann; Mahmoud Ibrahim; Robert Geffers; Chris Siebel; Berend Isermann; Florian H Heidel; Jonathan A Lindquist; Peter R Mertens Journal: J Am Soc Nephrol Date: 2020-08-28 Impact factor: 10.121
Authors: Rebecca Czolk; Niklas Schwarz; Henner Koch; Sonja Schötterl; Thomas V Wuttke; Per S Holm; Stephan M Huber; Ulrike Naumann Journal: Int J Mol Med Date: 2019-07-31 Impact factor: 4.101
Authors: Ronnie Morgenroth; Charlotte Reichardt; Johannes Steffen; Stefan Busse; Ronald Frank; Harald Heidecke; Peter R Mertens Journal: Cancers (Basel) Date: 2020-11-25 Impact factor: 6.639
Authors: Daria Mordovkina; Dmitry N Lyabin; Egor A Smolin; Ekaterina M Sogorina; Lev P Ovchinnikov; Irina Eliseeva Journal: Biomolecules Date: 2020-04-11
Authors: Sabine Brandt; Lara Ewert; Florian G Scurt; Charlotte Reichardt; Jonathan A Lindquist; Xenia Gorny; Berend Isermann; Peter R Mertens Journal: Sci Rep Date: 2019-12-13 Impact factor: 4.379
Authors: Christopher L Hessman; Josephine Hildebrandt; Aneri Shah; Sabine Brandt; Antonia Bock; Björn C Frye; Ute Raffetseder; Robert Geffers; Monika C Brunner-Weinzierl; Berend Isermann; Peter R Mertens; Jonathan A Lindquist Journal: Int J Mol Sci Date: 2020-09-25 Impact factor: 5.923